Cipla, country’s largest drug maker has reportedly slashed the prices of three anti-cancer drugs - Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). These drugs are used for the treatment of lung and pancreatic cancer, breast cancer, head and neck cancer, gastric cancer, bladder, colorectal and colon cancers.
The company has reported 61.83% rise in its net profit at Rs 500.01 crore as compared to Rs 308.97 crore for the same quarter in the previous year. Total income from operation of the company has increased by 23.86% at Rs 2191.84 crore for quarter under review as compared to Rs 1769.66 crore for the quarter ended September 30, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: